US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

ARS PHARMACEUTICALS INC

12.53

-0.0500-0.40%

Post-market: 12.00-0.5300-4.23%19:44 EDT

Volume:1.51M

Turnover:18.90M

Market Cap:1.23B

PE:156.63

High:12.85

Open:12.44

Low:12.23

Close:12.58

Loading ...

Overview Company News Filings

Raymond James Sticks to Its Buy Rating for ARS Pharmaceuticals (SPRY)

ARS Pharmaceuticals Inc : Raymond James Raises Target Price to $28 From $26

THOMSON REUTERS

ARS Pharmaceuticals Inc : Leerink Partners Raises Target Price to $27 From $26

THOMSON REUTERS

Corrected-ARS Pharmaceuticals Q4 Neffy Product Revenue of USD 6.5 Million (Corrects to Clarify Amount Is Not for Co's 'Revenue', and Removes Reference to Estimate)

THOMSON REUTERS

ARS Pharmaceuticals Q4 Revenue USD 6.5 Million VS. Ibes Estimate USD 17 Million

THOMSON REUTERS

Press Release: ARS Pharmaceuticals Announces Preliminary Fourth Quarter 2024 Financial Results and 2025 Objectives for neffy(R) (epinephrine nasal spray)

ARS Pharmaceuticals files for approval of neffy in Canada, U.K.

ARS Pharmaceuticals Files for Approval of Experimental Allergic Reaction Treatment in Canada, UK

MT Newswires Live

ARS Pharmaceuticals Files for Approval of Neffy® in Canada and the United Kingdom on Behalf of Licensing Partner Alk-AbellÓ a/S

THOMSON REUTERS

Institutional owners may ignore ARS Pharmaceuticals, Inc.'s (NASDAQ:SPRY) recent US$67m market cap decline as longer-term profits stay in the green

Simply Wall St.

ARS Pharmaceuticals adds neffy to Commercial national formularies

ARS Pharmaceuticals' Licensing Partners in China, Japan, Australia Seek Approval on Neffy Nasal Spray

MT Newswires Live

BRIEF-ARS Pharmaceuticals Announces Filings For Approval Of Neffy In China, Japan And Australia

ARS Pharmaceuticals notes filings for neffy approval in China, Japan, Australia

ARS Pharmaceuticals Announces Filings for Approval of Neffy® in China, Japan and Australia

THOMSON REUTERS

ARS Pharmaceuticals Announces Filings for Approval of neffy® in China, Japan and Australia

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SPRY/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SPRY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SPRY\",,,,,undefined,":{"symbol":"SPRY","market":"US","secType":"STK","nameCN":"ARS PHARMACEUTICALS INC","latestPrice":12.53,"timestamp":1743537600000,"preClose":12.58,"halted":0,"volume":1510874,"hourTrading":{"tag":"盘后","latestPrice":12,"preClose":12.53,"latestTime":"19:44 EDT","volume":29745,"amount":372521.37,"timestamp":1743551073955},"delay":0,"floatShares":47453121,"shares":98119804,"eps":0.079999,"marketStatus":"Not Yet Opened","change":-0.05,"latestTime":"04-01 16:00:00 EDT","open":12.44,"high":12.85,"low":12.229,"amount":18903210.909434,"amplitude":0.049364,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.079999,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1743580800000},"marketStatusCode":0,"adr":0,"listingDate":1607058000000,"exchange":"NASDAQ","adjPreClose":12.58,"preHourTrading":{"tag":"盘前","latestPrice":12.43,"preClose":12.58,"latestTime":"09:29 EDT","volume":386,"amount":4798.360017,"timestamp":1743514199999},"postHourTrading":{"tag":"盘后","latestPrice":12,"preClose":12.53,"latestTime":"19:44 EDT","volume":29745,"amount":372521.37,"timestamp":1743551073955},"volumeRatio":0.864809,"impliedVol":1.2136,"impliedVolPercentile":0.9323},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SPRY\",,,,,undefined,":{"symbol":"SPRY","floatShares":47453121,"roa":"-0.66%","roe":"3.28%","lyrEps":0.082507,"volumeRatio":0.864809,"shares":98119804,"dividePrice":0,"high":12.85,"amplitude":0.049364,"preClose":12.58,"low":12.229,"week52Low":7.55,"pbRate":"4.79","psRate":"13.79","week52High":18.51,"institutionHeld":0,"latestPrice":12.53,"eps":0.079999,"divideRate":0,"volume":1510874,"delay":0,"ttmEps":0.079999,"open":12.44,"prevYearClose":10.55,"prevWeekClose":12.49,"prevMonthClose":12.58,"prevQuarterClose":12.58,"fiveDayClose":13.15,"twentyDayClose":10.51,"sixtyDayClose":10.71},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SPRY\",pageSize:16,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2503257695","title":"Raymond James Sticks to Its Buy Rating for ARS Pharmaceuticals (SPRY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2503257695","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503257695?lang=en_us&edition=fundamental","pubTime":"2025-01-14 22:16","pubTimestamp":1736864164,"startTime":"0","endTime":"0","summary":"In a report released today, Ryan Deschner from Raymond James maintained a Buy rating on ARS Pharmaceuticals (SPRY – Research Report), with a price ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/raymond-james-sticks-to-its-buy-rating-for-ars-pharmaceuticals-spry?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/raymond-james-sticks-to-its-buy-rating-for-ars-pharmaceuticals-spry?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RJF","SPRY"],"gpt_icon":0},{"id":"2503221745","title":"ARS Pharmaceuticals Inc : Raymond James Raises Target Price to $28 From $26","url":"https://stock-news.laohu8.com/highlight/detail?id=2503221745","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503221745?lang=en_us&edition=fundamental","pubTime":"2025-01-14 20:47","pubTimestamp":1736858843,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250114:nFWN3OA162:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2503309634","title":"ARS Pharmaceuticals Inc : Leerink Partners Raises Target Price to $27 From $26","url":"https://stock-news.laohu8.com/highlight/detail?id=2503309634","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503309634?lang=en_us&edition=fundamental","pubTime":"2025-01-13 21:01","pubTimestamp":1736773295,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250113:nFWN3O916Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"2503589270","title":"Corrected-ARS Pharmaceuticals Q4 Neffy Product Revenue of USD 6.5 Million (Corrects to Clarify Amount Is Not for Co's 'Revenue', and Removes Reference to Estimate)","url":"https://stock-news.laohu8.com/highlight/detail?id=2503589270","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503589270?lang=en_us&edition=fundamental","pubTime":"2025-01-13 21:00","pubTimestamp":1736773201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250113:nPLX0C6208:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"2503098253","title":"ARS Pharmaceuticals Q4 Revenue USD 6.5 Million VS. Ibes Estimate USD 17 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2503098253","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503098253?lang=en_us&edition=fundamental","pubTime":"2025-01-13 21:00","pubTimestamp":1736773201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250113:nPLX0C6208:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRY"],"gpt_icon":0},{"id":"2503309516","title":"Press Release: ARS Pharmaceuticals Announces Preliminary Fourth Quarter 2024 Financial Results and 2025 Objectives for neffy(R) (epinephrine nasal spray)","url":"https://stock-news.laohu8.com/highlight/detail?id=2503309516","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503309516?lang=en_us&edition=fundamental","pubTime":"2025-01-13 21:00","pubTimestamp":1736773200,"startTime":"0","endTime":"0","summary":"Preliminary fourth quarter neffy net product revenue of approximately $6.5 million. Preliminary cash, cash equivalents and short-term investments of $314.0 million at year-end 2024 to support an operating runway of at least three years. Company to present at 43 Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 7:30am PT. SAN DIEGO, Jan. 13, 2025  -- ARS Pharmaceuticals, Inc. , a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today announced preliminary, unaudited neffy  net product revenue for the fourth quarter and full year 2024 and outlined its 2025 commercial and clinical objectives.-- Product revenue: Preliminary neffy net product revenue for the fourth. quarter of 2024 was approximately $6.5 million, with total net product. sales for 2024 of approximately $7.1 million since neffy became available. to wholesalers and pharmacies on Septemb","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237438978.USD","BK4139","LU0912757837.SGD","LU0950375773.USD","LU0795875086.SGD","IE00BGHQF631.EUR","LU0158827948.USD","LU2347655156.SGD","IE00BVYPNW00.USD","LU0823417653.USD","IE00B3PB1722.GBP","LU0823417737.USD","BK4561","LU1732800096.USD","LU2506951958.HKD","LU2506951875.HKD","BK4566","CME","IE00B3T34201.USD","LU2023251221.USD","BK4112","LU2089283258.USD","SPRY","LU2089284900.SGD","LU2506952170.USD","IE00BDGV0183.EUR","LU0731783394.SGD","LU2133065610.SGD","IE00BVYPNV92.GBP","BK4585","LU2506952097.USD","LU1599440770.SGD","R","BK4022","LU1718418525.SGD","LU1732799900.SGD","IE00B42XCP33.USD","LU0795875169.SGD","BK4232","BK4588"],"gpt_icon":0},{"id":"2501202154","title":"ARS Pharmaceuticals files for approval of neffy in Canada, U.K.","url":"https://stock-news.laohu8.com/highlight/detail?id=2501202154","media":"TipRanks","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501202154?lang=en_us&edition=fundamental","pubTime":"2025-01-07 21:15","pubTimestamp":1736255711,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals  announced that ARS Pharma has filed for approval of neffy 2 mg in Canada and the United Kingdom, where it will be marketed as EURneffy, on behalf of its licensing partner, ALK- Abello A/S. neffy was recently approved in the U.S. for the treatment of Type I Allergic Reactions, including anaphylaxis, in adults and children who weigh greater than or equal to30 kg. In November 2024, ARS Pharma announced a licensing agreement providing ALK with exclusive rights to commercialize neffy in Europe, Canada, United Kingdom and certain other geographies outside of the U.S.Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener. ARS Pharmaceuticals adds neffy to Commercial national formularies. ARS Pharmaceuticals notes filings for neffy approval in China, Japan, Australia. ARS Pharmaceuticals files for approval of neffy in China, Japan and Australia","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/ars-pharmaceuticals-files-approval-neffy-131511272.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ars-pharmaceuticals-files-approval-neffy-131511272.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2501519672","title":"ARS Pharmaceuticals Files for Approval of Experimental Allergic Reaction Treatment in Canada, UK","url":"https://stock-news.laohu8.com/highlight/detail?id=2501519672","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501519672?lang=en_us&edition=fundamental","pubTime":"2025-01-07 00:06","pubTimestamp":1736179562,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals  said Monday it has filed for approval of the neffy epinephrine nasal spray for the treatment of type I allergic reactions in Canada and the UK on behalf of its licensing partner, ALK-Abello.The company said it is assessing its intranasal epinephrine technology to treat acute flares in patients with chronic urticaria. It intends to initiate a phase 2b clinical trial early this year.ARS Pharmaceuticals also said its license deal with ALK will provide them exclusive rights for any new indication in the licensed territories under the agreement.Shares of the company declined more than 1% in recent trading activity.Price: 10.99, Change: -0.21, Percent Change: -1.83","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2501239028","title":"ARS Pharmaceuticals Files for Approval of Neffy® in Canada and the United Kingdom on Behalf of Licensing Partner Alk-AbellÓ a/S","url":"https://stock-news.laohu8.com/highlight/detail?id=2501239028","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501239028?lang=en_us&edition=fundamental","pubTime":"2025-01-06 21:14","pubTimestamp":1736169290,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250106:nFWN3O1023:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2493033776","title":"Institutional owners may ignore ARS Pharmaceuticals, Inc.'s (NASDAQ:SPRY) recent US$67m market cap decline as longer-term profits stay in the green","url":"https://stock-news.laohu8.com/highlight/detail?id=2493033776","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493033776?lang=en_us&edition=fundamental","pubTime":"2024-12-24 23:24","pubTimestamp":1735053852,"startTime":"0","endTime":"0","summary":"Given the large stake in the stock by institutions, ARS Pharmaceuticals' stock price might be vulnerable to their trading decisions. 54% of the business is held by the top 8 shareholders. To get a sense of who is truly in control of ARS Pharmaceuticals, Inc. , it is important to understand the ownership structure of the business. We can see that institutions own the lion's share in the company with 36% ownership. In other words, the group stands to gain the most  from their investment into the company.No shareholder likes losing money on their investments, especially institutional investors who saw their holdings drop 5.8% in value last week. However, the 117% one-year returns may have helped alleviate their overall losses. We would assume however, that they would be on the lookout for weakness in the future.Let's take a closer look to see what the different types of shareholders can tell us about ARS Pharmaceuticals.Check out our latest analysis for ARS Pharmaceuticals. What Does The ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/institutional-owners-may-ignore-ars-152412062.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MNQmain","SQQQ","USJW.SI","QLD","TQQQ","TSYW.SI","QID","IE00BGHQF748.EUR","BK4585","BK4139","NDAQ","LU2210150020.SGD","NQmain","BK4588","USAW.SI",".IXIC","LU2095319765.USD","LU2210149790.SGD","SPRY","BK4112","IE00B3QW5Z07.USD","NVIW.SI","IE00BKPKM429.USD","PSQ","IE00B64PRP62.GBP"],"gpt_icon":1},{"id":"2492577438","title":"ARS Pharmaceuticals adds neffy to Commercial national formularies","url":"https://stock-news.laohu8.com/highlight/detail?id=2492577438","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492577438?lang=en_us&edition=fundamental","pubTime":"2024-12-20 06:30","pubTimestamp":1734647418,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals (SPRY) “announced that Express Scripts, the pharmacy benefits business of Evernorth Health Services, has added neffy to its Com...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ars-pharmaceuticals-adds-neffy-to-commercial-national-formularies?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ars-pharmaceuticals-adds-neffy-to-commercial-national-formularies?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2491513333","title":"ARS Pharmaceuticals' Licensing Partners in China, Japan, Australia Seek Approval on Neffy Nasal Spray","url":"https://stock-news.laohu8.com/highlight/detail?id=2491513333","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491513333?lang=en_us&edition=fundamental","pubTime":"2024-12-13 04:36","pubTimestamp":1734035779,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals (SPRY) said its licensing partners in China, Japan and Australia have submitted approval applications for its epinephrine nasal spray called neffy 2 mg.The phase 3 trial of the nas","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","XAO.AU","XKO.AU","XJO.AU","SPRY"],"gpt_icon":0},{"id":"2491635667","title":"BRIEF-ARS Pharmaceuticals Announces Filings For Approval Of Neffy In China, Japan And Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2491635667","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491635667?lang=en_us&edition=fundamental","pubTime":"2024-12-13 03:54","pubTimestamp":1734033258,"startTime":"0","endTime":"0","summary":"BRIEF-ARS Pharmaceuticals Announces Filings For Approval Of Neffy In China, Japan And AustraliaDec 12 (Reuters) - ARS Pharmaceuticals Inc SPRY.O:ARS PHARMACEUTICALS ANNOUNCES FILINGS FOR APPROVAL OF N","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241212:nFWN3ND1MO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2491635614","title":"ARS Pharmaceuticals notes filings for neffy approval in China, Japan, Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2491635614","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491635614?lang=en_us&edition=fundamental","pubTime":"2024-12-13 03:45","pubTimestamp":1734032718,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals (SPRY) announced that its licensing partners in China, Japan and Australia have filed for approval of neffy epinephrine nasal s...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ars-pharmaceuticals-notes-filings-for-neffy-approval-in-china-japan-australia?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ars-pharmaceuticals-notes-filings-for-neffy-approval-in-china-japan-australia?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2491435573","title":"ARS Pharmaceuticals Announces Filings for Approval of Neffy® in China, Japan and Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2491435573","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491435573?lang=en_us&edition=fundamental","pubTime":"2024-12-13 03:32","pubTimestamp":1734031962,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241212:nFWN3ND1MO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2491356690","title":"ARS Pharmaceuticals Announces Filings for Approval of neffy® in China, Japan and Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2491356690","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491356690?lang=en_us&edition=fundamental","pubTime":"2024-12-13 03:32","pubTimestamp":1734031920,"startTime":"0","endTime":"0","summary":"Licensing partners in key Asia Pacific countries have filed for approval of neffy  2 mg with regulatory agencies. “Given the life-saving potential of neffy for the emergency treatment of severe allergic reactions, our focus is on making it available as quickly and as broadly as possible worldwide,” says Richard Lowenthal, Co-Founder, President and CEO of ARS Pharmaceuticals. “People in the Asia Pacific region could soon be saying hello to neffy where the unique attributes of the product, such as being needle-free, easy to dispose, a smaller size with temperature excursions up to 122°F , and a 30 month shelf life are particularly important. We are thankful to our licensing partners in these countries for filing with their respective regulatory agencies.”ARS Pharma retains all U.S. rights for neffy and has existing licensing partnerships in China, Japan, Australia and New Zealand with Pediatrix Therapeutics, Alfresa Pharma, and CSL Seqirus, respectively. ARS Pharma also has an exclusive ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/2662Y2FQHMfQLid_BOesTg--~B/aD0zMTE7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/58ce048b192bf8bfd3f62881dd68376c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/2662Y2FQHMfQLid_BOesTg--~B/aD0zMTE7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/58ce048b192bf8bfd3f62881dd68376c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ars-pharmaceuticals-announces-filings-approval-193200902.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SPRY","BK4139"],"gpt_icon":0}],"pageSize":16,"totalPage":8,"pageCount":5,"totalSize":116}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SPRY\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-20","symbol":"SPRY","fiscalQuarterEnding":"2024/12","expectedEps":-0.04,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1742443200000,"reportTimeType":"pre","actualEps":0.52},{"market":"US","date":"2025-01-13","symbol":"SPRY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1736744400000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2024-11-13","symbol":"SPRY","fiscalQuarterEnding":"2024/09","expectedEps":-0.18,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"pre","actualEps":-0.2},{"market":"US","date":"2024-08-06","symbol":"SPRY","fiscalQuarterEnding":"2024/06","expectedEps":-0.12,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1722916800000,"reportTimeType":"post","actualEps":-0.13},{"market":"US","date":"2024-05-09","symbol":"SPRY","fiscalQuarterEnding":"2024/03","expectedEps":-0.11,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715227200000,"reportTimeType":"post","actualEps":-0.11}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SPRY\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SPRY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6667,"buy":0.3333,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6667,"analysts":6,"updateTime":1741320000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SPRY\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SPRY","date":"2025-03-31","current":153.227851,"percent":0.991023,"low":-41.829007,"twenty":-28.717849,"median":-17.742813,"eighty":-12.537484,"high":175.555688,"avg":-17.968123,"sd":21.640669,"marketCap":1225516351},"quantilePoints":[{"date":"2022-11-11","current":-28.534516,"twenty":-28.349227,"median":-28.071294,"eighty":-27.904534,"marketCap":577624216},{"date":"2022-11-18","current":-27.515427,"twenty":-28.349227,"median":-28.00181,"eighty":-27.867476,"marketCap":556994780},{"date":"2022-11-25","current":-28.627161,"twenty":-29.164499,"median":-28.302905,"eighty":-27.978649,"marketCap":579499619},{"date":"2022-12-02","current":-32.332942,"twenty":-29.813011,"median":-28.534516,"eighty":-27.978649,"marketCap":654515751},{"date":"2022-12-09","current":-33.352032,"twenty":-32.629404,"median":-28.951417,"eighty":-27.987913,"marketCap":675145188},{"date":"2022-12-16","current":-37.428392,"twenty":-33.870842,"median":-29.970507,"eighty":-28.034236,"marketCap":757662933},{"date":"2022-12-23","current":-37.428392,"twenty":-36.761351,"median":-31.221208,"eighty":-28.136145,"marketCap":757662933},{"date":"2022-12-30","current":-39.512894,"twenty":-37.428392,"median":-32.842487,"eighty":-28.39555,"marketCap":799859507},{"date":"2023-01-06","current":-33.490999,"twenty":-37.558094,"median":-33.236227,"eighty":-28.506723,"marketCap":677958292},{"date":"2023-01-13","current":-34.510089,"twenty":-37.428392,"median":-33.352032,"eighty":-28.608632,"marketCap":698587729},{"date":"2023-01-20","current":-24.704541,"twenty":-37.261632,"median":-32.981454,"eighty":-28.089644,"marketCap":627322403},{"date":"2023-01-27","current":-23.338221,"twenty":-36.955904,"median":-32.518231,"eighty":-27.978649,"marketCap":592627442},{"date":"2023-02-03","current":-26.292426,"twenty":-36.631648,"median":-30.109473,"eighty":-26.233342,"marketCap":667643574},{"date":"2023-02-10","current":-28.323442,"twenty":-36.44636,"median":-29.576768,"eighty":-26.233342,"marketCap":719217165},{"date":"2023-02-17","current":-31.868488,"twenty":-36.103575,"median":-29.970507,"eighty":-27.026227,"marketCap":809236523},{"date":"2023-02-24","current":-30.539096,"twenty":-35.51065,"median":-30.109473,"eighty":-27.543213,"marketCap":775479264},{"date":"2023-03-03","current":-33.641011,"twenty":-34.760229,"median":-30.612951,"eighty":-27.668279,"marketCap":854246203},{"date":"2023-03-10","current":-29.025066,"twenty":-34.306271,"median":-30.649879,"eighty":-27.867476,"marketCap":737033496},{"date":"2023-03-17","current":-31.056082,"twenty":-33.963486,"median":-30.631415,"eighty":-27.978649,"marketCap":788607087},{"date":"2023-03-24","current":-20.659679,"twenty":-33.801144,"median":-30.612951,"eighty":-27.867476,"marketCap":716518982},{"date":"2023-03-31","current":-17.719962,"twenty":-33.618064,"median":-30.576023,"eighty":-26.2038,"marketCap":614563712},{"date":"2023-04-06","current":-15.732931,"twenty":-33.565575,"median":-30.176574,"eighty":-25.70897,"marketCap":545649501},{"date":"2023-04-14","current":-16.631178,"twenty":-33.492841,"median":-29.970507,"eighty":-24.113699,"marketCap":576802501},{"date":"2023-04-21","current":-17.973502,"twenty":-33.463206,"median":-29.344076,"eighty":-23.419462,"marketCap":623356984},{"date":"2023-04-28","current":-17.210989,"twenty":-33.352032,"median":-29.090384,"eighty":-19.070054,"marketCap":596911536},{"date":"2023-05-05","current":-16.693286,"twenty":-33.350744,"median":-28.918758,"eighty":-18.073817,"marketCap":578956528},{"date":"2023-05-12","current":-12.329028,"twenty":-33.323434,"median":-28.627161,"eighty":-17.841072,"marketCap":427595344},{"date":"2023-05-19","current":-17.294264,"twenty":-33.212652,"median":-28.359496,"eighty":-17.789501,"marketCap":733155735},{"date":"2023-05-26","current":-17.057707,"twenty":-33.123305,"median":-28.101877,"eighty":-17.789501,"marketCap":723127390},{"date":"2023-06-02","current":-15.358643,"twenty":-33.120421,"median":-28.024971,"eighty":-17.719962,"marketCap":651098973},{"date":"2023-06-09","current":-15.179795,"twenty":-32.981454,"median":-27.978649,"eighty":-17.665522,"marketCap":643517035},{"date":"2023-06-16","current":-13.525443,"twenty":-32.939388,"median":-27.584891,"eighty":-17.230009,"marketCap":573384103},{"date":"2023-06-23","current":-14.352619,"twenty":-32.898926,"median":-26.292426,"eighty":-16.984823,"marketCap":608450569},{"date":"2023-06-30","current":-14.777385,"twenty":-32.852687,"median":-26.033933,"eighty":-16.443167,"marketCap":626457673},{"date":"2023-07-07","current":-14.374975,"twenty":-32.778571,"median":-25.664657,"eighty":-16.200645,"marketCap":609398311},{"date":"2023-07-14","current":-15.381,"twenty":-32.650157,"median":-24.815323,"eighty":-15.896248,"marketCap":652046716},{"date":"2023-07-20","current":-16.342312,"twenty":-32.522678,"median":-23.947525,"eighty":-15.738555,"marketCap":692799635},{"date":"2023-07-28","current":-14.889165,"twenty":-32.268091,"median":-23.449004,"eighty":-15.666005,"marketCap":631196385},{"date":"2023-08-04","current":-15.649273,"twenty":-31.980646,"median":-22.434463,"eighty":-15.664922,"marketCap":663419624},{"date":"2023-08-11","current":-12.27233,"twenty":-31.772476,"median":-20.321699,"eighty":-15.577733,"marketCap":654642902},{"date":"2023-08-18","current":-12.05734,"twenty":-31.358888,"median":-18.902086,"eighty":-15.443597,"marketCap":643174706},{"date":"2023-08-25","current":-12.361909,"twenty":-31.218563,"median":-18.499284,"eighty":-15.287104,"marketCap":659421318},{"date":"2023-08-30","current":-12.70231,"twenty":-31.152094,"median":-18.359623,"eighty":-15.152968,"marketCap":677579296},{"date":"2023-09-08","current":-13.114373,"twenty":-31.100395,"median":-18.231502,"eighty":-15.005417,"marketCap":699560007},{"date":"2023-09-15","current":-13.04271,"twenty":-31.033926,"median":-18.031385,"eighty":-14.777385,"marketCap":695737274},{"date":"2023-09-20","current":-11.833393,"twenty":-31.022847,"median":-18.002563,"eighty":-14.750557,"marketCap":631228667},{"date":"2023-09-27","current":-6.718429,"twenty":-31.011769,"median":-17.988032,"eighty":-14.670075,"marketCap":358381151},{"date":"2023-10-05","current":-7.166324,"twenty":-30.867751,"median":-17.964938,"eighty":-14.419687,"marketCap":382273228},{"date":"2023-10-13","current":-6.718429,"twenty":-30.668342,"median":-17.875755,"eighty":-14.196126,"marketCap":358381151},{"date":"2023-10-20","current":-6.055544,"twenty":-30.649879,"median":-17.782874,"eighty":-14.047454,"marketCap":323020877},{"date":"2023-10-27","current":-6.306365,"twenty":-30.649879,"median":-17.728408,"eighty":-14.012806,"marketCap":336400440},{"date":"2023-11-03","current":-6.539271,"twenty":-30.635108,"median":-17.710569,"eighty":-13.713234,"marketCap":348824320},{"date":"2023-11-10","current":-5.319172,"twenty":-30.612951,"median":-17.665522,"eighty":-13.225451,"marketCap":327799293},{"date":"2023-11-17","current":-7.025405,"twenty":-30.612951,"median":-17.36121,"eighty":-12.859969,"marketCap":432947606},{"date":"2023-11-24","current":-7.41484,"twenty":-30.59818,"median":-17.220775,"eighty":-12.627063,"marketCap":456946919},{"date":"2023-12-01","current":-7.523882,"twenty":-30.480012,"median":-17.057707,"eighty":-12.494486,"marketCap":463666727},{"date":"2023-12-08","current":-8.1314,"twenty":-30.216835,"median":-16.553813,"eighty":-12.335604,"marketCap":501105655},{"date":"2023-12-15","current":-8.115823,"twenty":-30.090944,"median":-16.431736,"eighty":-12.243664,"marketCap":500145682},{"date":"2023-12-22","current":-7.944471,"twenty":-30.007565,"median":-16.309818,"eighty":-8.996418,"marketCap":489585985},{"date":"2023-12-29","current":-8.770073,"twenty":-29.979771,"median":-16.222884,"eighty":-8.287174,"marketCap":540464528},{"date":"2024-01-05","current":-8.785651,"twenty":-29.917293,"median":-16.174641,"eighty":-8.399331,"marketCap":541424501},{"date":"2024-01-12","current":-9.112776,"twenty":-29.704533,"median":-16.005127,"eighty":-8.58626,"marketCap":561583924},{"date":"2024-01-19","current":-9.471056,"twenty":-29.440705,"median":-15.977907,"eighty":-8.629876,"marketCap":583663292},{"date":"2024-01-26","current":-10.156461,"twenty":-29.180978,"median":-15.857321,"eighty":-8.707763,"marketCap":625902083},{"date":"2024-02-02","current":-9.969533,"twenty":-29.156298,"median":-15.732931,"eighty":-8.773189,"marketCap":614382412},{"date":"2024-02-09","current":-10.109729,"twenty":-29.07732,"median":-15.682807,"eighty":-8.798113,"marketCap":623022165},{"date":"2024-02-16","current":-11.309188,"twenty":-29.025066,"median":-15.649273,"eighty":-8.900923,"marketCap":696940049},{"date":"2024-02-23","current":-11.83882,"twenty":-29.025066,"median":-15.515136,"eighty":-9.112776,"marketCap":729579115},{"date":"2024-03-01","current":-13.038279,"twenty":-28.81245,"median":-15.453657,"eighty":-9.20624,"marketCap":803496999},{"date":"2024-03-08","current":-13.941768,"twenty":-28.8035,"median":-15.381,"eighty":-9.20624,"marketCap":859175405},{"date":"2024-03-15","current":-14.019655,"twenty":-28.627161,"median":-15.258041,"eighty":-9.237395,"marketCap":863975268},{"date":"2024-03-22","current":-15.975609,"twenty":-28.534516,"median":-15.179795,"eighty":-9.252972,"marketCap":868513986},{"date":"2024-03-28","current":-17.679674,"twenty":-28.423343,"median":-15.269219,"eighty":-9.315282,"marketCap":961155477},{"date":"2024-04-05","current":-16.916395,"twenty":-28.337864,"median":-15.369822,"eighty":-9.405631,"marketCap":919659809},{"date":"2024-04-12","current":-16.401625,"twenty":-28.264358,"median":-15.43689,"eighty":-9.46171,"marketCap":891674358},{"date":"2024-04-19","current":-14.981571,"twenty":-28.131419,"median":-15.49278,"eighty":-9.483518,"marketCap":814473115},{"date":"2024-04-26","current":-14.360297,"twenty":-28.077411,"median":-15.403356,"eighty":-9.636176,"marketCap":780697571},{"date":"2024-05-03","current":-16.860498,"twenty":-28.034236,"median":-15.420123,"eighty":-9.72341,"marketCap":916620967},{"date":"2024-05-10","current":-17.157732,"twenty":-27.987913,"median":-15.505955,"eighty":-9.779488,"marketCap":852670667},{"date":"2024-05-17","current":-17.742813,"twenty":-27.978649,"median":-15.537492,"eighty":-9.809086,"marketCap":881746829},{"date":"2024-05-24","current":-17.157885,"twenty":-27.978649,"median":-15.649273,"eighty":-9.876069,"marketCap":852678252},{"date":"2024-05-31","current":-17.372359,"twenty":-27.867476,"median":-15.716341,"eighty":-9.910338,"marketCap":863336730},{"date":"2024-06-07","current":-17.19688,"twenty":-27.668279,"median":-15.746992,"eighty":-9.932147,"marketCap":854616157},{"date":"2024-06-14","current":-17.430851,"twenty":-27.557105,"median":-15.857321,"eighty":-9.95084,"marketCap":866243588},{"date":"2024-06-21","current":-15.071642,"twenty":-27.270827,"median":-15.857321,"eighty":-9.975764,"marketCap":749000328},{"date":"2024-06-28","current":-15.695565,"twenty":-26.781626,"median":-15.857321,"eighty":-9.988225,"marketCap":780006810},{"date":"2024-07-05","current":-17.723315,"twenty":-26.233342,"median":-15.924221,"eighty":-10.038073,"marketCap":880777877},{"date":"2024-07-12","current":-21.66183,"twenty":-26.100403,"median":-16.005127,"eighty":-10.100383,"marketCap":1076506294},{"date":"2024-07-15","current":-22.129772,"twenty":-26.078246,"median":-16.005127,"eighty":-10.103498,"marketCap":1099761155},{"date":"2024-08-02","current":-20.452979,"twenty":-26.05609,"median":-16.005127,"eighty":-10.106614,"marketCap":1016431235},{"date":"2024-08-09","current":-21.380681,"twenty":-25.915765,"median":-16.072487,"eighty":-10.122191,"marketCap":958752513},{"date":"2024-08-16","current":-29.271428,"twenty":-26.174258,"median":-16.163463,"eighty":-10.15023,"marketCap":1312589385},{"date":"2024-08-23","current":-27.693279,"twenty":-27.713295,"median":-16.214626,"eighty":-10.468009,"marketCap":1241822011},{"date":"2024-08-30","current":-28.060793,"twenty":-27.98643,"median":-16.295121,"eighty":-10.844982,"marketCap":1258302084},{"date":"2024-09-06","current":-25.401719,"twenty":-27.994212,"median":-16.393243,"eighty":-10.985179,"marketCap":1139063905},{"date":"2024-09-13","current":-27.304146,"twenty":-27.978649,"median":-16.401625,"eighty":-11.047488,"marketCap":1224372521},{"date":"2024-09-20","current":-32.125068,"twenty":-28.0393,"median":-16.454093,"eighty":-11.125375,"marketCap":1440552309},{"date":"2024-09-27","current":-31.368421,"twenty":-28.102738,"median":-16.474539,"eighty":-11.25311,"marketCap":1406622746},{"date":"2024-10-04","current":-30.265879,"twenty":-28.279129,"median":-16.592455,"eighty":-11.496117,"marketCap":1357182526},{"date":"2024-10-11","current":-30.071312,"twenty":-28.572704,"median":-16.658407,"eighty":-11.620736,"marketCap":1348457781},{"date":"2024-10-18","current":-34.870616,"twenty":-28.814446,"median":-16.809891,"eighty":-11.676815,"marketCap":1563668153},{"date":"2024-10-25","current":-33.292466,"twenty":-29.051193,"median":-16.869409,"eighty":-11.785716,"marketCap":1492900778},{"date":"2024-10-31","current":-30.849578,"twenty":-29.236068,"median":-16.900657,"eighty":-11.835564,"marketCap":1383356760},{"date":"2024-11-08","current":-34.892234,"twenty":-29.613,"median":-17.040899,"eighty":-11.890396,"marketCap":1564637569},{"date":"2024-11-15","current":-27.926178,"twenty":-29.784002,"median":-17.157809,"eighty":-12.003593,"marketCap":1371287052},{"date":"2024-11-22","current":-26.481379,"twenty":-29.677856,"median":-17.19688,"eighty":-12.129003,"marketCap":1300341655},{"date":"2024-11-29","current":-28.717849,"twenty":-29.625971,"median":-17.210989,"eighty":-12.243664,"marketCap":1410161242},{"date":"2024-12-06","current":-27.708469,"twenty":-29.56544,"median":-17.223194,"eighty":-12.275913,"marketCap":1360596650},{"date":"2024-12-13","current":-25.016789,"twenty":-29.525705,"median":-17.313866,"eighty":-12.298002,"marketCap":1228424404},{"date":"2024-12-20","current":-22.404276,"twenty":-29.458385,"median":-17.352861,"eighty":-12.329028,"marketCap":1100139577},{"date":"2024-12-27","current":-22.067816,"twenty":-29.271428,"median":-17.394358,"eighty":-12.329028,"marketCap":1083618046},{"date":"2025-01-03","current":-21.196979,"twenty":-29.200708,"median":-17.429503,"eighty":-12.355333,"marketCap":1040856437},{"date":"2025-01-10","current":-22.621986,"twenty":-29.176877,"median":-17.469847,"eighty":-12.383408,"marketCap":1110829979},{"date":"2025-01-17","current":-24.106368,"twenty":-29.123341,"median":-17.508842,"eighty":-12.41924,"marketCap":1183719085},{"date":"2025-01-24","current":-27.490759,"twenty":-29.064257,"median":-17.592246,"eighty":-12.455071,"marketCap":1349906247},{"date":"2025-01-31","current":-28.28243,"twenty":-29.064257,"median":-17.626125,"eighty":-12.501652,"marketCap":1388780437},{"date":"2025-02-07","current":-25.333457,"twenty":-29.025066,"median":-17.679674,"eighty":-12.537484,"marketCap":1243974080},{"date":"2025-02-14","current":-23.591782,"twenty":-29.002547,"median":-17.701176,"eighty":-12.573316,"marketCap":1158450862},{"date":"2025-02-21","current":-23.314697,"twenty":-28.938503,"median":-17.719962,"eighty":-12.598398,"marketCap":1144844895},{"date":"2025-02-28","current":-20.187599,"twenty":-28.816442,"median":-17.723315,"eighty":-12.627063,"marketCap":991291845},{"date":"2025-03-07","current":-21.355313,"twenty":-28.81066,"median":-17.742813,"eighty":-12.687977,"marketCap":1048631275},{"date":"2025-03-14","current":-23.651157,"twenty":-28.793317,"median":-17.742813,"eighty":-12.709476,"marketCap":1161366426},{"date":"2025-03-21","current":175.555688,"twenty":-28.745638,"median":-17.756493,"eighty":-12.709476,"marketCap":1404094395},{"date":"2025-03-28","current":154.945377,"twenty":-28.717849,"median":-17.742813,"eighty":-12.566149,"marketCap":1239253124},{"date":"2025-03-31","current":153.227851,"twenty":-28.717849,"median":-17.742813,"eighty":-12.537484,"marketCap":1225516351}],"updateTime":1743553255004}}}